Review of heart transplantation from hepatitis C-positive donors  

作　　者：Palak Patel Nirav Patel Fahad Ahmed Jason Gluck 

机构地区：[1]Department of Cardiology,West Roxbury VA Center,West Roxbury,MA 02132,United States [2]Department of Cardiology,University of Connecticut,Harford Hospital,Hartford,CT 06102,United States [3]Department of Cardiology,University of California,CA 90065,United States [4]Department of Internal Medicine,Hartford Hospital,Hartford,CT 06106,United States [5]Advanced Heart Failure,Hartford Hospital,Hartford,CT 06102,United States

出　　处：《World Journal of Transplantation》2022年第12期394-404,共11页世界移植杂志

摘　　要：Significant scarcity of a donor pool exists for heart transplantation(HT)as the prevalence of patients with end-stage refractory heart failure is increasing exceptionally.With the discovery of effective direct-acting antiviral and favorable short-term outcomes following HT,the hearts from hepatitis C virus(HCV)patient are being utilized to increase the donor pool.Short-term outcomes with regards to graft function,coronary artery vasculopathy,and kidney and liver disease is comparable in HCV-negative recipients undergoing HT from HCVpositive donors compared to HCV-negative donors.A significant high incidence of donor-derived HCV transmission was observed with great success of achieving sustained viral response with the use of direct-acting antivirals.By accepting HCV-positive organs,the donor pool has expanded with younger donors,a shorter waitlist time,and a reduction in waitlist mortality.However,the longterm outcomes and impact of specific HCV genotypes remains to be seen.We reviewed the current literature on HT from HCV-positive donors.

关 键 词：Heart transplant Hepatitis C-positive donors Direct-acting antiviral Coronary allograft vasculopathy Allograft rejection 

分 类 号：R51[医药卫生—内科学]